Pharma News

New Phase II data presented at SLEuro 2026 support enpatoran’s Phase III development in cutaneous lupus and systemic lupus erythematosus.

Quantum Biopharma plans to seek FDA clearance for a Phase 2 U.S. trial of Lucid-MS, an oral therapy aimed at myelin repair in multiple sclerosis.

Biogen announced FDA approval of the high dose SPINRAZA regimen for spinal muscular atrophy, expanding treatment options for SMA patients.

HLB said the FDA granted priority review to lirafugratinib for bile duct cancer, with a decision expected by Sept. 27.

Eli Lilly deepens its AI drug discovery strategy through a new Insilico Medicine partnership worth up to $2.75 billion in milestones and royalties.

Italian pharma Recordati weighs a €10.9bn acquisition offer from CVC Capital. Discover the details of this major M&A deal ahead of the Q1 2026 close.

Simulations Plus announces strategic partnerships with three pharmaceutical companies to integrate AI into model-informed drug development workflows.

Wave Life Sciences' stock crashed 50% after its Phase I obesity trial for WVE-007 showed lower-than-expected weight loss, disappointing investors.

The FDA has approved Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults living with type 2 diabetes to improve A1C.

Ipsen's valuation comes into focus following new preclinical data at AACR for first-in-class oncology candidates IPN01203 and IPN60300 in solid tumors.

Experimental MS therapy CDR111, developed by CDR-Life and Boehringer Ingelheim, advances after meeting a key preclinical milestone in B-cell depletion.

A new theory proposes Alzheimer's is an autoimmune disease of the brain's immune system, challenging the 30-year-old beta-amyloid cascade hypothesis.